Posner Christopher
Known title: DirectorCIK: 0001748265
Associated companies
Transaction History
| TVRD | ▼ Sell | Open Market | 583 | $3K | 2/28/2025 | View on chart |
| TVRD | ▼ Sell | Open Market | 372 | $2K | 2/4/2025 | View on chart |
| TVRD | ▼ Sell | Open Market | 3,668 | $1K | 11/4/2024 | View on chart |
| TVRD | ▼ Sell | Open Market | 4,149 | $1K | 8/1/2024 | View on chart |
| TVRD | ▼ Sell | Open Market | 3,936 | $3K | 5/2/2024 | View on chart |
| TVRD | ▼ Sell | Open Market | 5,834 | $5K | 2/29/2024 | View on chart |
| TVRD | ▼ Sell | Open Market | 35,575 | $19K | 2/8/2024 | View on chart |
| TVRD | ▲ Buy | Grant | 62,500 | $0 | 2/1/2024 | View on chart |
| TVRD | ▼ Sell | Open Market | 4,981 | $3K | 2/1/2024 | View on chart |
| TVRD | ▼ Sell | Open Market | 3,796 | $5K | 11/2/2023 | View on chart |
| TVRD | ▼ Sell | Open Market | 4,307 | $13K | 8/3/2023 | View on chart |
| TVRD | ▼ Sell | Open Market | 3,869 | $17K | 5/5/2023 | View on chart |
| TVRD | ▼ Sell | Open Market | 5,987 | $58K | 3/3/2023 | View on chart |
| TVRD | ▼ Sell | Open Market | 4,191 | $49K | 2/2/2023 | View on chart |
| TVRD | ▼ Sell | Open Market | 14,470 | $161K | 11/16/2022 | View on chart |
| TVRD | ▼ Sell | Open Market | 2,006 | $25K | 4/4/2022 | View on chart |
| TVRD | ▲ Buy | Grant | 39,000 | $0 | 2/25/2022 | View on chart |
| TVRD | ▲ Buy | Grant | 5,941 | $0 | 10/29/2021 | View on chart |
| TVRD | ▲ Buy | Grant | 142,000 | $0 | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tvardi releases preclinical data on STAT3 inhibitor for UC
Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.
Tvardi releases preclinical data on STAT3 inhibitor for UC. Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.